ClinicalTrials.gg
Not yet recruitingNCT07907991Updated Nov 10, 2026

The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of Verducatib and Placebo matching verducatib in Chronic Obstructive Pulmonary Disease, sponsored by Boehringer Ingelheim. Not yet recruiting at 26 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026First sites in Italy, Malaysia and United StatesPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,800
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Boehringer Ingelheim.

Planned enrollment
11th of 155
1,800 · median 166
Started
2027
the only one that year
Phase 3
81 of 236
1 open now
Registered
236th of 236
by date

Among the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, this one is the 11th largest by planned enrollment of the 155 interventional ones that give a count, is the only one that started in 2027, is one of 81 in phase 3, and was the 236th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim is open now, in 3 countries.

By country, each count listing its studies:

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to adults aged 40 years and older who have chronic obstructive pulmonary disease (COPD) with ongoing symptoms. People can join the study if they are at risk of COPD flare-ups (also called acute exacerbations or sudden worsening of COPD symptoms) even though they use their usual inhaled or oral COPD medicines. They must have had at least 2 moderate COPD flare-ups or at least 1 severe COPD flare-up in the past year, including at least 1 while taking their current COPD treatment. People must also have a blood test result showing less than 300 eosinophils (a type of white blood cell) per microliter. The purpose of this study is to find out whether a medicine called verducatib helps people with COPD have fewer flare-ups or sudden worsening of COPD symptoms over up to about 1.5 years, compared with placebo. The study also looks at whether verducatib delays the time until the first flare-up, how well it is tolerated, improves participants' quality of life, and improves their lung function when compared with placebo.

In this study, participants are put into 2 groups randomly, which means by chance. One group takes verducatib as tablets and the other group takes placebo tablets. Placebo tablets look like verducatib tablets but do not contain any medicine. Participants take a tablet by mouth once a day for at least 1 year and up to about 1.5 years. All participants continue their regular COPD treatment during the study.

Participants are in the study for at least 1 year and up to about 1 year and 8 months. During this time, they have regular visits at the study site and monthly phone calls from the study staff to check on their COPD symptoms and any health problems. Doctors collect information about participants' health, including blood samples. They record how often participants have moderate or severe COPD flare-ups and how long it takes until the first flare-up. They also measure lung function and ask participants to fill in questionnaires about their symptoms and daily life. Participants have to daily report their symptoms and intake of certain medications in an electronic diary at home. The results are compared between the 2 groups to see whether verducatib helps reduce flare-ups and improves symptoms. The doctors also regularly check participants' health and note any unwanted effects.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • exacerbations
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥40 years
  • Diagnosis of (COPD) for at least 12 months prior to screening according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition
  • Post-bronchodilator (BD) (FEV1)/forced vital capacity [FVC] \<0.70 at screening and baseline
  • Post-BD forced expiratory volume in 1 second percent predicted (FEV1pp) ≥30% at screening
  • Current or former cigarette smokers with a smoking history ≥10 pack years history of cigarette smoking
  • Chronic Airways Disease Assessment Test (CAAT) score ≥10 at screening with cough and sputum sub-scores of ≥ 2
  • Documented history of ≥2 moderate or ≥1 severe exacerbations within 12 months prior to screening. At least one exacerbation must have occurred while participants were on their current COPD maintenance therapy
  • Stable standard of care considered appropriate by the investigator for at least 3 months prior to screening with either

    • Triple therapy Long-acting beta agonist (LABA) + Long-acting muscarinic antagonist (LAMA) + Inhaled (ICS)
    • Double therapy LAMA+LABA Additional medications, e.g. as per local COPD guidelines should also be stable for at least 3 months
  • Blood eosinophil count \<300 cells/µL at screening Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of asthma, prior history of asthma, or asthma- overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18
  • pulmonary disease other than COPD, e.g. sarcoidosis, interstitial lung disease, alpha-1 antitrypsin deficiency
  • Past or current diagnosis of bronchiectasis or bronchiectasis-COPD overlap as assessed by the investigator
  • estimated (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \<30 mL/min at screening
  • Upper and lower respiratory tract infection within 4 weeks prior to screening or during the screening and randomisation period
  • Participants with bronchoscopic interventional procedures up to 3 years prior to screening
  • Prior history of or planned pneumonectomy or lung volume reduction surgery.
  • Participants who are participating in the acute phase of a pulmonary rehabilitation or smoking-cessation program, i.e. who started such program \< 4 weeks prior screening
  • Moderate or severe Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) within 4 weeks prior to screening or between screening and randomisation Further exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,800 participants (estimated)

Study arms

  • Experimental
    Verducatib treatment group

    Drug: Verducatib

  • Placebo comparator
    Placebo group

    Drug: Placebo matching verducatib

Interventions

  • Verducatib

  • DrugPlacebo matching verducatib

    Placebo matching verducatib

06

What researchers measure

Primary outcomes

  1. Annualised rate of moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (number of events per person per year)

    Time frame: Up to week 76

Secondary outcomes

  1. Time to first moderate or severe AECOPD

    Time frame: Up to week 76

  2. Time to first severe AECOPD

    Time frame: Up to week 76

  3. Achievement of St George's Respiratory Questionnaire (SGRQ) response (decrease in total score by ≥4 points from baseline) at week 52

    SGRQ consists of 50 items covering symptoms, activity and impacts on daily life with varying response options (3 to 5-point Likert scales, dichotomous response option). Domain scores as well as a global score are generated ranging from 0 to 100, with lower scores indicating better health related Quality of Life (QoL).

    Time frame: At baseline and at week 52

  4. Absolute change from baseline in post-Bronchodilator (BD) forced expiratory volume in 1 second (FEV1) (milliliters) at week 52

    Time frame: At baseline and at week 52

  5. Annualised rate of severe AECOPD

    Time frame: Up to week 76

  6. Absolute change from baseline in SGRQ total score at week 52

    Time frame: At baseline and at week 52

  7. Achievement of Evaluating Respiratory Symptoms E-RS: COPD response (decrease by ≥2 points from baseline) at week 52

    E-RS:COPD is an 11-item respiratory symptom score derived from the 14-item Exacerbations of chronic pulmonary disease tool (EXACT)-COPD diary and is used to assess the severity of daily respiratory symptoms in patients with stable COPD. It covers exacerbation-related symptoms breathlessness (5 items), cough and sputum (3 items), and chest symptoms (3 items). These items sum up to a total score ranging from 0 to 40, with higher scores indicating higher symptom severity.

    Time frame: At baseline and at week 52

  8. Achievement of Chronic Airways Disease Assessment Test (CAAT) response (decrease by ≥2 points from baseline) at week 52

    CAAT is designed to measure health status impairment in chronic airways disease; it consists of 8 unidimensional items with scores ranging from 0 to 5 (0 = no impairment). The total score ranges from 0 - 40 with a higher score indicating a worse health status of the patient.

    Time frame: At baseline and at week 52

  9. Absolute change from baseline in post-BD Forced expiratory volume in 1 second percent predicted (FEV1pp) at week 52

    Time frame: At baseline and at week 52

07

Study locations

26 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined on the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Nov 2029, 32 months later.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 32 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2029 → Nov 2029 and completion Jan 2030 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Oct 30, 2026
StartEst.
Mar 10, 2027
Primary completionEst.
Nov 12, 2029was Dec 2029
CompletionEst.
Dec 10, 2029was Jan 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
26 sites added — first sites in Italy, Malaysia and United States
Show 26 added (18 United States, 4 Italy, 4 Malaysia)
  • University of Alabama at Birmingham · Birmingham, United States
  • Pulmonary Associates - Deer Valley Office · Phoenix, United States
  • IMAX Clinical Trials · La Palma, United States
  • Clinical Research Specialists LLC - Kissimmee · Kissimmee, United States
  • Optimus U Corporation-Miami-69452 · Miami, United States
  • Cordova Research Institute · Miami, United States
  • Bolanos Clinical Research · Pembroke Pines, United States
  • Appalachian Clinical Research · Adairsville, United States
  • Covenant Pulmonary Critical Care · Atlanta, United States
  • Christie Clinic in Champaign on University · Champaign, United States
  • Brigham and Women's Hospital · Boston, United States
  • UMASS Memorial Medical Center · Worcester, United States
  • Midwest Clinical Research Center - St. Louis · St Louis, United States
  • Clinical Research Associates of Central PA · DuBois, United States
  • Temple University · Philadelphia, United States
  • Velocity Clinical Research-Union-68888 · Union, United States
  • Clinical Trials Center of Middle Tennessee, LLC · Franklin, United States
  • Greater Heights & Memorial Pulmonary and Sleep · Houston, United States
  • Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico · Milan, Italy
  • ASST Fatebenefratelli Sacco · Milan, Italy
  • Azienda Ospedaliera Universitaria "Federico II" · Naples, Italy
  • Pol. Universitario Tor Vergata · Roma, Italy
  • Hospital Sultan Idris Shah Serdang · Kajang, Malaysia
  • Hospital Raja Perempuan Zainab II · Kelantan, Malaysia
  • Institut Perubatan Respiratori · Kuala Lumpur, Malaysia
  • University Malaya Medical Centre · Kuala Lumpur, Malaysia
Nov 10, 2026
Primary completion
Dec 12, 2029→Nov 12, 2029
Nov 10, 2026
Study completion
Jan 9, 2030→Dec 10, 2029
Nov 10, 2026
Registered
First appeared on the registry
Oct 30, 2026
Show all 2 updates
  1. Nov 10, 2026
    26 sites added — first sites in Italy, Malaysia and United States
    Show 26 added (18 United States, 4 Italy, 4 Malaysia)
    • University of Alabama at Birmingham · Birmingham, United States
    • Pulmonary Associates - Deer Valley Office · Phoenix, United States
    • IMAX Clinical Trials · La Palma, United States
    • Clinical Research Specialists LLC - Kissimmee · Kissimmee, United States
    • Optimus U Corporation-Miami-69452 · Miami, United States
    • Cordova Research Institute · Miami, United States
    • Bolanos Clinical Research · Pembroke Pines, United States
    • Appalachian Clinical Research · Adairsville, United States
    • Covenant Pulmonary Critical Care · Atlanta, United States
    • Christie Clinic in Champaign on University · Champaign, United States
    • Brigham and Women's Hospital · Boston, United States
    • UMASS Memorial Medical Center · Worcester, United States
    • Midwest Clinical Research Center - St. Louis · St Louis, United States
    • Clinical Research Associates of Central PA · DuBois, United States
    • Temple University · Philadelphia, United States
    • Velocity Clinical Research-Union-68888 · Union, United States
    • Clinical Trials Center of Middle Tennessee, LLC · Franklin, United States
    • Greater Heights & Memorial Pulmonary and Sleep · Houston, United States
    • Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico · Milan, Italy
    • ASST Fatebenefratelli Sacco · Milan, Italy
    • Azienda Ospedaliera Universitaria "Federico II" · Naples, Italy
    • Pol. Universitario Tor Vergata · Roma, Italy
    • Hospital Sultan Idris Shah Serdang · Kajang, Malaysia
    • Hospital Raja Perempuan Zainab II · Kelantan, Malaysia
    • Institut Perubatan Respiratori · Kuala Lumpur, Malaysia
    • University Malaya Medical Centre · Kuala Lumpur, Malaysia
    Primary completion Dec 12, 2029→Nov 12, 2029
    Study completion Jan 9, 2030→Dec 10, 2029
    + 1 other change: verification date
  2. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07907991
Responsible party
Sponsor
First posted
Oct 30, 2026
Start date
Mar 10, 2027 (estimated)
Primary completion
Nov 12, 2029 (estimated)
Completion
Dec 10, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
018002430127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verducatib

Start the discussion